Processa Pharmaceuticals (PCSA) Insider Neal Buys 203 Shares

James Neal Buys Processa Stock

James Neal recently picked up shares of Processa Pharmaceuticals, Inc. (NasdaqCM: PCSA), adding to a busy stretch of insider transactions at the clinical-stage biopharmaceutical company. The transaction was logged on June 26, 2026, catching the attention of market watchers tracking leadership moves at the Vero Beach, Florida-based firm.

Recent Insider Activity at Processa

Leadership trades have picked up across the company lately. On June 26, 2026, Khoso Baluch bought 203 shares, while Justin Yorke parted with 203 shares on the same date. Earlier in the month on June 15, 2026, Patrick Lin, who serves as the Chief Business and Strategy Officer, bought 1,831 shares at an average price of $2.22 for a total value of $4,064.82. These transactions show ongoing adjustments to equity ownership among key people at the organization.

Processa Stock Valuation and Trading

The shares recently changed hands around $1.92. That sits above the 52-week low of $1.67, though it remains far below the 52-week high of $14.25. The company has a P/E ratio of 2.83 and carries a market cap of roughly $5.14 million.

Inside the Pipeline at Processa Pharmaceuticals

Processa focuses on building better cancer therapies by tweaking existing FDA-approved drugs to improve safety and how the body handles them. Its main oncology candidate, NGC-Cap, is currently undergoing Phase 2 clinical trials for multiple solid tumors, including breast and colorectal cancers. The enterprise also works on non-oncology treatments such as PCS499 for primary glomerular diseases and PCS12852 for gastroparesis.

What to Watch Next for PCSA

Observers will likely keep an eye on upcoming SEC filings for any further insider adjustments or corporate developments. The company's next earnings report is anticipated around August 11, 2025, which should provide a fresh look at financial progress.